Cargando…
Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma
BACKGROUND: Diffuse large B-cell lymphoma, among non-Hodgkin lymphomas, is one of the most frequent subtypes. Clinical laboratory data and post-treatment outcomes are scarce in the Brazilian population. OBJECTIVE: The main objective of this retrospective study was to assess the impact of tumor marke...
Autores principales: | Fogliatto, Laura, Grokoski, Kamila Castro, Strey, Yuri Machado, Vanelli, Tito, Fraga, Christina Garcia da Silva, Barra, Marines Bizarro, Pinto, Fernanda Correa, Bendit, Israel, Bica, Claúdia Giuliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371411/ https://www.ncbi.nlm.nih.gov/pubmed/30793105 http://dx.doi.org/10.1016/j.htct.2018.05.014 |
Ejemplares similares
-
What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?
por: Bosi, Guilherme Rasia, et al.
Publicado: (2019) -
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020) -
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
por: Saikh, Kamal U.
Publicado: (2021) -
Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022) -
A MyD88 meddles with survival
por: Bashyam, Hema
Publicado: (2007)